Keel Point LLC decreased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 4.5% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 7,175 shares of the medical research company’s stock after selling 342 shares during the quarter. Keel Point LLC’s holdings in Thermo Fisher Scientific were worth $3,743,000 as of its most recent SEC filing.
A number of other institutional investors also recently modified their holdings of the company. Bornite Capital Management LP boosted its holdings in Thermo Fisher Scientific by 50.0% in the first quarter. Bornite Capital Management LP now owns 30,000 shares of the medical research company’s stock worth $17,719,000 after acquiring an additional 10,000 shares in the last quarter. Fairfield Bush & CO. raised its holdings in shares of Thermo Fisher Scientific by 1.2% in the first quarter. Fairfield Bush & CO. now owns 2,928 shares of the medical research company’s stock valued at $1,729,000 after purchasing an additional 36 shares during the last quarter. Loomis Sayles & Co. L P boosted its holdings in Thermo Fisher Scientific by 563.5% during the first quarter. Loomis Sayles & Co. L P now owns 19,844 shares of the medical research company’s stock worth $11,721,000 after purchasing an additional 16,853 shares during the last quarter. Covestor Ltd grew its position in Thermo Fisher Scientific by 60.5% in the 1st quarter. Covestor Ltd now owns 321 shares of the medical research company’s stock worth $190,000 after purchasing an additional 121 shares in the last quarter. Finally, Merit Financial Group LLC lifted its position in shares of Thermo Fisher Scientific by 3.6% during the 1st quarter. Merit Financial Group LLC now owns 669 shares of the medical research company’s stock worth $395,000 after buying an additional 23 shares in the last quarter. 87.06% of the stock is owned by institutional investors.
Analyst Ratings Changes
A number of analysts recently commented on TMO shares. Credit Suisse Group raised Thermo Fisher Scientific from a “neutral” rating to an “outperform” rating and set a $620.00 price target for the company in a research report on Thursday, July 13th. JPMorgan Chase & Co. boosted their price target on shares of Thermo Fisher Scientific from $660.00 to $670.00 in a report on Thursday, July 27th. Barclays raised their price objective on shares of Thermo Fisher Scientific from $590.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, July 27th. Raymond James increased their target price on shares of Thermo Fisher Scientific from $595.00 to $630.00 and gave the company an “outperform” rating in a research report on Friday, July 28th. Finally, Royal Bank of Canada upped their price objective on Thermo Fisher Scientific from $662.00 to $698.00 in a research note on Thursday, July 27th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $631.71.
Insiders Place Their Bets
In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $549.00, for a total transaction of $5,490,000.00. Following the completion of the transaction, the chief executive officer now owns 141,330 shares of the company’s stock, valued at $77,590,170. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Gianluca Pettiti sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, August 30th. The stock was sold at an average price of $557.77, for a total transaction of $1,673,310.00. Following the transaction, the executive vice president now directly owns 17,556 shares of the company’s stock, valued at approximately $9,792,210.12. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction that occurred on Thursday, August 3rd. The shares were sold at an average price of $549.00, for a total transaction of $5,490,000.00. Following the transaction, the chief executive officer now owns 141,330 shares in the company, valued at $77,590,170. The disclosure for this sale can be found here. Insiders have sold 28,700 shares of company stock worth $15,799,270 in the last ninety days. 0.32% of the stock is currently owned by insiders.
Thermo Fisher Scientific Price Performance
NYSE TMO traded down $3.15 during trading hours on Tuesday, hitting $504.58. The company had a trading volume of 324,781 shares, compared to its average volume of 1,493,450. The firm has a 50 day simple moving average of $540.37 and a 200 day simple moving average of $541.53. Thermo Fisher Scientific Inc. has a 52 week low of $475.77 and a 52 week high of $609.85. The firm has a market capitalization of $194.74 billion, a price-to-earnings ratio of 34.72, a PEG ratio of 2.43 and a beta of 0.77. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.02 and a current ratio of 1.42.
Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last issued its quarterly earnings data on Wednesday, July 26th. The medical research company reported $5.15 EPS for the quarter, missing the consensus estimate of $5.43 by ($0.28). Thermo Fisher Scientific had a net margin of 13.14% and a return on equity of 18.59%. The firm had revenue of $10.69 billion for the quarter, compared to analysts’ expectations of $10.99 billion. During the same period in the prior year, the firm posted $5.51 EPS. Thermo Fisher Scientific’s revenue was down 2.6% on a year-over-year basis. Equities research analysts expect that Thermo Fisher Scientific Inc. will post 22.37 earnings per share for the current year.
Thermo Fisher Scientific Dividend Announcement
The firm also recently announced a quarterly dividend, which will be paid on Friday, October 13th. Investors of record on Friday, September 15th will be given a dividend of $0.35 per share. This represents a $1.40 annualized dividend and a yield of 0.28%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s payout ratio is 9.57%.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
- Five stocks we like better than Thermo Fisher Scientific
- Investing in the Best Airline Stocks
- 2 Beauty Stocks Beaten By the Ugly Stick But Ready to Rally
- How to Invest in Pharmaceutical Companies
- Got Nuclear? Three Stocks To Play Energy’s Next Frontier
- 3 Natural Gas Stocks That Offer Great Dividend Yields
- The Top 4 Utilities for Value, Yield, and Upside Potential
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.